GBS Inc. is on a mission to put the power of non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point of care. With the world-first Biosensor Platform, GBS Inc. is developing and launching diagnostic tests urgently needed to help eradicate COVID-19 and change the lives of people living with diabetes.

$0.74  +0.01 (0.74%)
As of 06/27/2022 16:00:01 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Medical Devices
Index country:  USA
Country of incorporation:  USA
IPO date:  12/23/2020
Outstanding shares:  14,889,904
Average volume:  95,028
Market cap:   $11,006,617
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Valuation   (See tab for details)
PE ratio:   -1.95
PB ratio:   1.26
PS ratio:   56.54
Return on equity:   -41.31%
Net income %:   -1,861.91%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy